APA (7th ed.) Citation

Provan, S. A., Berg, I. J., Hammer, H. B., Mathiessen, A., Kvien, T. K., & Semb, A. G. (2015). The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab. PLoS ONE, 10(6), 1. https://doi.org/10.1371/journal.pone.0130709

Chicago Style (17th ed.) Citation

Provan, Sella Aarrestad, Inger Jorid Berg, Hilde Berner Hammer, Alexander Mathiessen, Tore Kristian Kvien, and Anne Grete Semb. "The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab." PLoS ONE 10, no. 6 (2015): 1. https://doi.org/10.1371/journal.pone.0130709.

MLA (9th ed.) Citation

Provan, Sella Aarrestad, et al. "The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab." PLoS ONE, vol. 10, no. 6, 2015, p. 1, https://doi.org/10.1371/journal.pone.0130709.